Pfizer Stock: Buy, Sell, or Hold?
The company is entering what could be a particularly challenging period.
Since 2021, Pfizer's (NYSE: PFE) shares have been trading below the $30 mark for over two years. Following impressive financial results driven by its coronavirus-related products, the company's revenue and earnings dipped due to Pfizer's inability to maintain that momentum. However, Pfizer has recently bolstered its pipeline, and in the coming years, substantial clinical and regulatory advancements could be on the horizon.
The question remains: is Pfizer stock a buy, sell, or hold for the medium term? This analysis will explore whether Pfizer stock is a buy, sell, or hold.
Despite Pfizer no longer generating the sales and earnings it once did, the company has outperformed expectations in recent quarters. Over the past decade, Pfizer has exceeded revenue estimates in nine out of the last ten quarterly reporting periods and earnings per share estimates in all ten. However, Pfizer could face challenges in the next few years as the company navigates major patent cliffs. The pharmaceutical giant will lose patent exclusivity for Eliquis, a key growth driver, by the end of the decade.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- Pfizer Stock: Buy, Sell, or Hold? nasdaq.com
